DRC & Research News

This page shares the latest news in T1D research and DRC’s community.

Get the most recent diabetes research news, delivered straight to your inbox

Nanoparticles

Leveraging Nanoparticles in Diagnosing and Treating Type 1 Diabetes

Leveraging Nanoparticles in Diagnosing and Treating Type 1 Diabetes

Medical technology has seen significant advancements over the years helping to improve healthcare in many ways. An area of recent focus has been nanotechnology. Researchers have been exploring opportunities to use nanomedicine to expand upon current diagnosis and treatment options for type 1 diabetes, which affects millions of people around the world.

For instance, scientists know that a key marker for type 1 diabetes (T1D) is the destruction of insulin-producing beta cells. But oftentimes these cellular changes are not noticed until they become severe enough that symptoms of high blood sugar are apparent. Being able to identify biomarkers earlier can improve the diagnosis of the disease and allow patients to receive treatment sooner.

A recent study examines the use of nanoparticles to support the diagnosis of T1D as well as treatment options. Pairing the nanoparticle ferumoxytol with current magnetic resonance imaging (MRI) technology may enable healthcare providers to better visualize where there is inflammation within pancreatic islets. These nanoparticles readily accumulate in inflamed islets but then are safely metabolized by the body without any harmful side effects. Inflammation is an early sign of the development of T1D.

In addition, nanoparticles can also be loaded up with various substances such as peptides and injected to specific locations to target key processes like the downregulation of immune cells. This may help slow or prevent the destruction of insulin-producing beta cells. Or, nanotechnology could be used to encapsulate cells or molecules with bioparticles to ward off immune system attacks.

While more research is necessary, there is a great deal of opportunity that may exist for using nanotechnology and nanoparticles in healthcare. It could one day open new doors for the diagnosis and treatment of conditions such as type 1 diabetes or improve existing therapies.

Funding research around T1D is vital. Diabetes Research Connection (DRC) is committed to providing early-career scientists with funding to support novel research studies focused on prevention and management of the disease as well as improving quality of life and reducing complications of T1D. Learn more about current projects and how to support these efforts by visiting https://diabetesresearchconnection.org.

Learn More +

OUR PROJECTS

See our approved research projects and campaigns.

Role of the integrated stress response in type 1 diabetes pathogenesis
In individuals with type 1 diabetes (T1D), the insulin-producing beta cells are spontaneously destroyed by their own immune system. The trigger that provokes the immune system to destroy the beta cells is unknown. However, accumulating evidence suggest that signals are perhaps first sent out by the stressed beta cells that eventually attracts the immune cells. Stressed cells adapt different stress mitigation systems as an adaptive response. However, when these adaptive responses go awry, it results in cell death. One of the stress response mechanisms, namely the integrated stress response (ISR) is activated under a variety of stressful stimuli to promote cell survival. However, when ISR is chronically activated, it can be damaging to the cells and can lead to cell death. The role of the ISR in the context of T1D is unknown. Therefore, in this DRC funded study, we propose to study the ISR in the beta cells to determine its role in propagating T1D.
Wearable Skin Fluorescence Imaging Patch for the Detection of Blood Glucose Level on an Engineered Skin Platform
zhang
A Potential Second Cure for T1D by Re-Educating the Patient’s Immune System
L Ferreira
Validating the Hypothesis to Cure T1D by Eliminating the Rejection of Cells From Another Person by Farming Beta Cells From a Patient’s Own Stem Cells
Han Zhu
Taming a Particularly Lethal Category of Cells May Reduce/Eliminate the Onset of T1D
JRDwyer 2022 Lab 1
Can the Inhibition of One Specific Body Gene Prevent Type 1 Diabetes?
Melanie
Is Cholesterol Exacerbating T1D by Reducing the Functionality and Regeneration Ability of Residual Beta Cells?
Regeneration Ability of Residual Beta Cells
A Call to Question… Is T1D Caused by Dysfunctionality of Two Pancreatic Cells (β and α)?
Xin Tong
Novel therapy initiative with potential path to preventing T1D by targeting TWO components of T1D development (autoimmune response and beta-cell survival)
flavia pecanha